Differentiated Solutions for Long-term Resolution of Chronic Autoimmunity

A multinational biopharmaceutical company, with a long‑standing presence in rheumatology, immuno‑dermatology, bone disorders and neurological conditions, such as epilepsy, is now expanding their well-established activities in the immunology therapeutic area, with an ambition to bring transformational change to patients across priority disease indications focused on autoimmunity. This company is actively seeking approaches with potential for resolution and/or “reset” of the immune system with the potential to achieve long‑term disease and drug‑free remission in autoimmune disease. 

Approaches of Interest

• Therapeutic approaches to treat primary rheumatology (including but not limited to: psoriatic arthritis, axial spondylarthritis, rheumatoid arthritis and systemic lupus erythematosus), and secondary rheumatology diseases (including but not limited to: fibromyalgia and polymyalgia rheumatica)
• Therapeutic approaches to treat primary dermatology (including but not limited to: psoriasis, hidradenitis suppurativa and atopic dermatitis), and secondary dermatology diseases (including but not limited to: chronic spontaneous urticaria, phemphigoid/pemphigus, alopecia and vitiligo)
• Approaches that include long term/extended disease and drug‑free remission and infrequent dosing intervals (e.g., B cell depletion, rituximab‑like pharmacodynamics) are of the highest interest, with a prioritised modality focus on small molecules, antibodies and gene therapy
• Approaches that allow for earlier diagnosis and therefore therapeutic interventions, with the potential to improve patient remission rates and/or achieving extended low/no disease activity, and for tissue protection/restoration will also be considered

Out of Scope

• Approaches involving antigen‑specific peptide immunotherapy/tolerance, regulatory T cell‑based approaches, cell‑based therapy, drug repurposing, immunosuppressants or immunotherapy, and oncology are excluded 

Developmental Stages of Interest

• Opportunities at preclinical research phase to Phase I clinical trial are within scope
• Opportunities that are translational and can be connected to human populations are of the highest interest

Submission Information

Submission of one page, 200-300 word briefs are encouraged along with any optional supplementary information e.g., relevant publications and patents. In submitting to this campaign, you confirm that your submission contains only non-confidential information.

Opportunity for Collaboration

The client is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include licensing assets, research collaborations, and scope for co-inventorship and patent protection.